In vitro effects of glucose polymer-containing peritoneal dialysis fluids on phagocytic activity

American Journal of Kidney Diseases

Volumn 29, Issue 2, 1997, Pages 246-253

  Thomas, Stefan ^b   Schenk, Uwe ^b   Fischer, Frank Peter ^b   Mettang, Thomas ^b   Passlick Deetjen, Jutta ^b   Kuhlmann, Ulrich ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b NONE

Author keywords

biocompatibility; continuous ambulatory peritoneal dialysis; glucose polymer; host defense; osmolarity; Peritoneal dialysis; phagocytic activity

Indexed keywords

DIALYSIS FLUID;

ADULT; AGED; ARTICLE; BACTERICIDAL ACTIVITY; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; NEUTROPHIL; PHAGOCYTE; PHAGOCYTOSIS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 0030897099     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90037-8     Document Type: Article

References (29)

1. Duwe AK, Vas SI, Weatherhead JW: Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bacterial activity in vitro. Infect Immun 33:130-135, 1981
2. Alobaidi H, Coles G, Davies M, Lloyd D: Host defence in continuous ambulatory peritoneal dialysis: The effect of dialysate on phagocyte function. Nephrol Dial Transplant 1:16-21, 1986
3. Topley N, Alobaidi H, Davies M, Coles G, Williams J, Lloyd D: The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int 34:404-411, 1988
4. Passlick-Deetjen J: The importance of biocompatibility in peritoneal dialysis solutions. Perit Dial Int 13:S101-S104, 1993 (suppl 2)
5. Breborowicz A: In vitro study on the biocompatibility of the peritoneal dialysis solution. Perit Dial Int 13:S105-S107, 1993 (suppl 2)
6. Holmes CJ: Biocompatibility of peritoneal dialysis solutions. Perit Dial Int 13:88-94, 1993 (editorial)
7. Liberek T, Topley N, Jörres A, Coles G, Gahl GM, Williams JD: Peritoneal dialysis fluid inhibition of phagocyte function. Effects of osmolality and glucose concentration. J Am Soc Nephrol 3:1508-1515, 1993
8. Kjellstrand P, Martinson E, Wieslander A, Holmquist B: Development of toxic degradation products during heat sterilization of glucose-containing fluids for peritoneal dialysis: Influence of time and temperature. Perit Dial Int 15:26-32, 1995
9. Henderson I, Couper I, Lumsden A: Potentially irritant glucose metabolites in unused CAPD-fluid, in Mahler J, Winchester J (eds): Third Symposium on Peritoneal Dialysis. Washington, DC, Field Rich, 1984, pp 85-88
10. Topley N, Coles GA, Williams JD: Biocompatibility studies on peritoneal cells. Perit Dial Int 14:S21-S28, 1994 (suppl 3)
11. Breborowicz A, Rodela H, Oreopoulos DG: Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int 41:1280-1285, 1992
12. Breborowicz A, Rodela H, Pagiamtzis J, Diamandis E, Oreopoulos DG: Glucose (G) toxicity to human mesothelial cells (MC) in vitro. Nephrol Dial Transplant 10:S19, 1990 (suppl 1; abstr)
13. Breborowicz A: In vitro study on the biocompatibility of the peritoneal dialysis solution. Perit Dial Int 13:S105-S107, 1993 (suppl 2)
14. Hutchinson AJ, Gokal R: Improved solutions for peritoneal dialysis: Physiological calcium solutions, osmotic agents and buffers. Kidney Int 42:S153-S159, 1992 (suppl 38)
15. Martis L, Holmes C, Shockley T: Experimental peritoneal dialysis solutions. Perit Dial Int 13:S98-S100, 1993 (suppl 2)
16. Gokal R, Mistry CD: Glucose polymer as osmotic agent in CAPD, in La Greca G, Ronco C, Feriani M, Chairamonte S, Conz P (eds): Peritoneal Dialysis. Milan, Italy, Wichtig Editore, 1991, pp 119-123
17. Mistry CD, Gokal R: Can ultrafiltration occur with a hypo-osmolar solution in peritoneal dialysis? The role for colloid osmosis. Clin Sci 85:495-500, 1993
18. Mistry CD, Gokal R, Peers E, and the MIDAS Study Group: Randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int 46:496-503, 1994
19. Mistry CD, Gokal R: Single daily overnight (12-h dwell) use of 7.5% glucose polymer (Mw 18700; Mn 7300) +0.35% glucose solution: A 3-month study. Nephrol Dial Transplant 8:443-447, 1993
20. Stein A, Peers E, Harris K, Feehally J, Walls J: Glucose polymer for ultrafiltration failure in CAPD. Lancet 341:1159, 1993 (letter)
21. Gokal R, Mistry CD, Peers E, and the MIDAS Study Group: Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. Pent Dial Int 15:226-230, 1995
22. Liberek T, Topley N, Mistry CD, Coles GA, Morgan T, Quirk RA, Williams JD: Cell function and viability in glucose polymer peritoneal dialysis fluids. Perit Dial Int 13:104-111, 1993
23. De Fijter CWA, Verbrugh HA, Oe LP, Heezius E, Donker AJM, Verhoef J, Gokal R: Biocompatibility of a glucose polymer-containing peritoneal dialysis fluid. Am J Kidney Dis 21:411-418, 1993
24. Jörres A, Gahl M, Topley N, Topley N, Ludat K, Müller C, Passlick-Deetjen J: In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions. Nephrol Dial Transplant 9:785-790, 1994
25. Boyum A: Isolation of mononuclear cells and granulocytes from human blood: Isolation of mononuclear cells by one centrifugation and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest 21:77-89, 1968 (suppl 97)
26. Peterson PK, Verhoef J, Schmeling D, Quie PG: Kinetics of phagocytosis and bacterial killing by human polymorphonuclear leukocytes and monocytes. J Infect Dis 136:502-509, 1977
27. Hübel E, Kiefer T, Weber J, Mettang T, Kuhlmann U: In vivo effect of 1,25 dihydroxyvitamin D3 on phagocyte function in hemodialysis patients. Kidney Int 40:927-933, 1991
28. Babior BM, Kipnes RS, Curnette JT: Biological defense mechanism. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 52:741-744, 1973
29. Quie PG, White JG, Holmes B, Good RA: In vitro bactericidal capacity of human polymorphonuclear leukocytes: Diminished activity in chronic granulomatous disease of childhood. J Clin Invest 46:668-679, 1967